OTC Watch

All stocks / PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. PVCT

Provectus Biopharmaceuticals (PVCT): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated float OTCQBTennessee, USA
Live quote on OTC Markets

Market listing

Full name
PROVECTUS BIOPHARMACEUTICALS INC
Market tier
OTCQB
Trading status
Active
Last trade
09:31:28
Website
www.pvct.com
Source: Stockwatch, 2026-11-17

News headlines

VisiRose Selected to Present RB-PDAT at ESCRS iNovation(TM) Day 2026 Emerging Company Showcase
2026-07-22 08:00 · News Release
Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose
2026-07-07 08:00 · News Release
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
2026-06-30 08:00 · News Release
Provectus Biopharmaceuticals Launches Veripure(TM), an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
2026-06-25 08:00 · News Release
Provectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders
2026-06-08 08:00 · News Release
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
2026-05-18 08:00 · News Release
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus's VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
2026-05-04 08:00 · News Release
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
2026-04-20 18:09 · News Release
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
2026-04-02 08:00 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Revenue
$336,108
Net loss
($5,430,851)
What it means

It spends more than it earns

Under strain

Customers paid it $336,108 in the year. It lost $5.4 million. For every $1 that came in, about $17.16 went out.

The report says
Cash and cash equivalents
$251,291
Net cash used in operating activities
($3,325,991)
What it means

The cash could run out soon

Under strain

It had $251,291 in the bank and used about $277,166 a month. At that pace the money lasts less than a month unless it borrows or sells more shares.

The report says
Total assets
$697,502
Total liabilities
$7,000,220
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $697,502. Its debts and unpaid bills add up to $7 million. That is about $10.04 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-10

Estimated float about 420,279,879 shares as of 2026-11-10: 420,279,879 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-12-31
420.3M
2026-03-23
420.3M
2026-03-31
420.3M
2026-05-12
420.3M
2026-06-30
420.3M
2026-08-11
420.3M
2026-09-30
420.3M
2026-11-10
420.3M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 44
2026-11-10 10-Q10-Q
2026-11-09 44
2026-10-30 44
2026-10-23 44
2026-10-13 44
2026-10-05 44
2026-09-18 44
2026-09-11 44
2026-09-08 44
2026-08-26 44
2026-08-13 10-Q10-Q

Common questions about PVCT

Does PVCT file reports with the SEC?

Yes. Provectus Biopharmaceuticals files with the SEC under company number 0000315545. The most recent filing we hold is a 4 dated 2026-11-16.

Source record

How many PVCT shares are outstanding?

420,279,879 shares as of 2026-11-10, as reported to the SEC.

Source record

Has PVCT filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Provectus Biopharmaceuticals?

Officers named in its insider filings: Edward Pershing (CEO) and Dominic Rodrigues (PRESIDENT).

Source record

Is Provectus Biopharmaceuticals making money?

Customers paid it $336,108 in the year. It lost $5.4 million. For every $1 that came in, about $17.16 went out. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record